Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Change in Receivables (2021 - 2025)

Apellis Pharmaceuticals (APLS) has 5 years of Change in Receivables data on record, last reported at $20.7 million in Q4 2025.

  • For Q4 2025, Change in Receivables rose 246.78% year-over-year to $20.7 million; the TTM value through Dec 2025 reached $101.3 million, up 73.17%, while the annual FY2025 figure was $101.3 million, 73.17% up from the prior year.
  • Change in Receivables reached $20.7 million in Q4 2025 per APLS's latest filing, down from $131.4 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $131.4 million in Q3 2025 and bottomed at -$29.7 million in Q1 2025.
  • Average Change in Receivables over 5 years is $20.3 million, with a median of $4.7 million recorded in 2021.
  • Peak YoY movement for Change in Receivables: skyrocketed 10284.38% in 2023, then plummeted 157.74% in 2025.
  • A 5-year view of Change in Receivables shows it stood at $7.5 million in 2021, then crashed by 104.88% to -$365000.0 in 2022, then surged by 10284.38% to $37.2 million in 2023, then tumbled by 137.89% to -$14.1 million in 2024, then soared by 246.78% to $20.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were $20.7 million in Q4 2025, $131.4 million in Q3 2025, and -$21.1 million in Q2 2025.